GlassScriptPhysician profile
Ernesto Rodriguez
NPI 1457546731
$958,128.33
in general payments reported to CMS, 2019-2025
40 companies · $132K in 2025
The $132K reported for 2025 was more than what 98% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $227K · 2020: $74K · 2021: $80K · 2022: $130K · 2023: $153K · 2024: $163K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $334K · Travel and Lodging: $43K · Food and Beverage: $27K · Consulting Fee: $27K · Honoraria: $16K · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $334,015.00 |
| Travel and Lodging | $42,874.89 |
| Food and Beverage | $27,016.03 |
| Consulting Fee | $26,815.75 |
| Honoraria | $16,200.00 |
| Education | $259.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $475,135.23 | 2019-2025 | Evenity, Otezla, Uplizna |
| Abbvie INC. | $157,042.67 | 2019-2025 | Rinvoq, Skyrizi |
| Lilly USA, LLC | $97,617.19 | 2019-2025 | Taltz, Olumiant, Zepbound |
| Genzyme Corporation | $94,688.56 | 2019-2025 | |
| Horizon Therapeutics Plc | $52,332.31 | 2019-2023 | Krystexxa, Uplizna |
| Celgene Corporation | $32,975.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13,859.87 | 2019-2023 | Cosentyx |
| Pfizer INC. | $11,702.20 | 2019-2025 | |
| Janssen Biotech, INC. | $4,909.65 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Regeneron Healthcare Solutions, INC. | $3,528.18 | 2019 | |
| Ucb, INC. | $2,820.88 | 2019-2025 | Bimzelx, Cimzia |
| Glaxosmithkline, LLC. | $1,623.01 | 2021-2025 | Benlysta, Nucala |
| Abiomed | $1,504.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $1,269.15 | 2019-2025 | Saphnelo |
| Mallinckrodt Hospital Products INC. | $1,041.01 | 2020-2025 | Acthar |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $1,009.06 | 2021-2025 | Lupkynis |
| Gilead Sciences, INC. | $974.13 | 2020-2023 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $736.17 | 2019-2025 | Orencia |
| Sobi, INC | $486.45 | 2019-2025 | |
| Genentech USA, INC. | $402.54 | 2019-2025 | Actemra, Gazyva |
| Fresenius Kabi USA, LLC | $385.08 | 2023-2025 | Idacio, Tyenne |
| Boehringer Ingelheim Pharmaceuticals, INC. | $342.00 | 2019-2025 | Ofev, Cyltezo |
| Sanofi-Aventis U.S. LLC | $243.78 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $207.51 | 2023-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $187.15 | 2021-2025 | Opsumit, Uptravi |
| Organon LLC | $153.12 | 2024-2025 | Nexplanon, Hadlima |
| Genentech, INC. | $140.71 | 2021 | |
| Abbott Laboratories | $121.28 | 2023 | Dragonfly Opstar |
| Radius Health, INC. | $111.98 | 2019-2025 | Tymlos |
| Mckesson Specialty Care Distribution, LLC | $107.28 | 2019-2020 | |
| Kyowa Kirin, INC. | $100.11 | 2023-2025 | Crysvita |
| Medtronic, INC. | $80.11 | 2024 | Kyphon Express II Kyphopak Tray |
| Pacira Therapeutics, INC. | $69.99 | 2019 | |
| Zyla Life Sciences, INC. | $53.24 | 2019 | |
| Scilex Pharmaceuticals INC. | $47.76 | 2024 | |
| Zimmer Biomet Holdings, INC. | $45.70 | 2023 | Advantagerib |
| Alexion Pharmaceuticals, INC. | $38.18 | 2019-2025 | Strensiq |
| Kiniksa Pharmaceuticals International, Plc | $20.19 | 2024 | Arcalyst |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.65 | 2025 | Caplyta |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ernesto Rodriguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.